These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27281861)

  • 41. Swiss consensus on the role of DHEA in the management of genitourinary syndrome of menopause.
    Stute P; Bertschy S; Birkhaeuser M; Bitzer J; Ging A; Raggi A; Steimann S; Stute V
    Climacteric; 2022 Jun; 25(3):246-256. PubMed ID: 34907824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estrogen ring use for genitourinary atrophy and menopausal symptomatology.
    Thacker HL
    Geriatrics; 2004 May; 59(5):34, 36-7. PubMed ID: 15152734
    [No Abstract]   [Full Text] [Related]  

  • 43. [The role of estriol in therapy of urogenital disorders in postmenopausal women].
    Perepanova TS; Khazan PL
    Urologiia; 2007; (3):102-4, 107. PubMed ID: 17722629
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause.
    Bondi C; Ferrero S; Scala C; Tafi E; Racca A; Venturini PL; Leone Roberti Maggiore U
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1233-46. PubMed ID: 27476551
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Topical hormonal treatment and urogenital atrophy].
    Sitruk-Ware R; Thomas JL
    Praxis (Bern 1994); 1997 Aug; 86(33):1245-8. PubMed ID: 9381009
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
    Gandhi J; Chen A; Dagur G; Suh Y; Smith N; Cali B; Khan SA
    Am J Obstet Gynecol; 2016 Dec; 215(6):704-711. PubMed ID: 27472999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaginal hormone therapy for urogenital and menopausal symptoms.
    Ballagh SA
    Semin Reprod Med; 2005 May; 23(2):126-40. PubMed ID: 15852198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer: Clinical Consensus.
    Obstet Gynecol; 2021 Dec; 138(6):950-960. PubMed ID: 34794166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A review of transdermal nonpatch estrogen therapy for the management of menopausal symptoms.
    Carroll N
    J Womens Health (Larchmt); 2010 Jan; 19(1):47-55. PubMed ID: 20088658
    [TBL] [Abstract][Full Text] [Related]  

  • 50. From systemic hormone therapy to vaginal estrogen - a nationwide register study in Finland, 2003-2012.
    Holm E; Aaltonen K; Heikkinen AM; Tiihonen M
    Maturitas; 2014 Aug; 78(4):293-7. PubMed ID: 24934885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
    North American Menopause Society
    Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Local oestrogen replacement for local symptoms in older community dwelling women.
    Fonda D
    Gerontology; 1994; 40 Suppl 3():9-13. PubMed ID: 7851802
    [No Abstract]   [Full Text] [Related]  

  • 53. Revitalizing research in genitourinary syndrome of menopause.
    Chang OH; Paraiso MFR
    Am J Obstet Gynecol; 2019 Mar; 220(3):246.e1-246.e4. PubMed ID: 30586548
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of vaginal estrogen in Danish women: a nationwide cross-sectional study.
    Meaidi A; Goukasian I; Lidegaard O
    Acta Obstet Gynecol Scand; 2016 Mar; 95(3):280-4. PubMed ID: 26646469
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [CO
    Jardin I; Canlorbe G; Mergui JL; Nikpayam M; Belghiti J; Uzan C; Azaïs H
    Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):729-734. PubMed ID: 30241737
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estrogens--pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation--Estring.
    Johnston A
    Acta Obstet Gynecol Scand Suppl; 1996; 163():16-25. PubMed ID: 8916471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trends in oral and vaginally administered estrogen use among US women 50 years of age or older with commercial health insurance.
    Weissfeld JL; Liu W; Woods C; Zhang R; Li J; van der Vlugt TH; Slaughter SR
    Menopause; 2018 Jun; 25(6):611-614. PubMed ID: 29286985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Healthcare provider knowledge, attitudes, and preferences in management of genitourinary syndrome of menopause in the Mid-South.
    Morris J; Clark C; Reed L; Pace D; Cao X; Khanna P
    Menopause; 2021 Aug; 28(11):1239-1246. PubMed ID: 34469937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms.
    Utian WH; Speroff L; Ellman H; Dart C
    Menopause; 2005; 12(6):708-15. PubMed ID: 16278614
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Urogenital estrogen deficiency syndrome. Investigation and treatment with special reference to hormone substitution].
    Eriksen BC; Hunskår S
    Tidsskr Nor Laegeforen; 1991 Oct; 111(24):2949-51. PubMed ID: 1948898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.